What is HC Wainwright’s Forecast for CRDL FY2024 Earnings?

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Analysts at HC Wainwright upped their FY2024 earnings estimates for shares of Cardiol Therapeutics in a research note issued to investors on Wednesday, November 20th. HC Wainwright analyst V. Bernardino now forecasts that the company will earn ($0.38) per share for the year, up from their prior estimate of ($0.44). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ Q4 2024 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

Cardiol Therapeutics Trading Up 1.0 %

NASDAQ CRDL opened at $1.58 on Friday. The stock has a market capitalization of $128.52 million, a price-to-earnings ratio of -4.04 and a beta of 0.91. Cardiol Therapeutics has a 52 week low of $0.79 and a 52 week high of $3.12. The stock’s 50 day moving average price is $1.95 and its two-hundred day moving average price is $2.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.49 and a current ratio of 2.49.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Townsquare Capital LLC acquired a new position in Cardiol Therapeutics during the third quarter valued at approximately $27,000. Wealth Enhancement Advisory Services LLC acquired a new position in Cardiol Therapeutics during the third quarter worth $27,000. Jane Street Group LLC bought a new stake in Cardiol Therapeutics during the third quarter worth $29,000. Baader Bank Aktiengesellschaft acquired a new stake in Cardiol Therapeutics in the second quarter valued at $59,000. Finally, Foundations Investment Advisors LLC bought a new position in shares of Cardiol Therapeutics in the 2nd quarter valued at about $97,000. Institutional investors own 12.49% of the company’s stock.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.